| Date | Title | Description |
| 15.12.2021 | Checkmate Pharmaceuticals : Corporate Overview – December 2021 | Heating Up Cancer Immunotherapy
December 2021
Forward Looking Statement
Certain statements in this presentation ("Presentation") that are not statements of historical facts may constitute forward-looking statements within the mean... |
| 19.11.2021 | Checkmate Pharmaceuticals : Corporate Overview – November 2021 | Heating Up Cancer Immunotherapy
November 2021
Forward Looking Statement
Certain statements in this presentation ("Presentation") that are not statements of historical facts may constitute forward-looking statements within the mean... |
| 03.11.2021 | Checkmate Pharmaceuticals Corporate Overview – November 2021 | Heating Up Cancer Immunotherapy
November 2021
Forward Looking Statement
Certain statements in this presentation ("Presentation") that are not statements of historical facts may constitute forward-looking statements within the mean... |
| 28.10.2021 | Checkmate Pharmaceuticals Corporate Overview – October 2021 | Heating Up Cancer Immunotherapy
October 2021
Forward Looking Statement
Certain statements in this presentation ("Presentation") that are not statements of historical facts may constitute forward-looking statements within the meani... |
| 04.05.2021 | CHECKMATE PHARMACEUTICALS, INC.
Checkmate Pharmaceuticals : Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advan... | CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune ... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IP... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know:
– Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies.
– LVP4 will invest opportunistica... |
| 04.08.2020 | IPO Launch: Checkmate Pharmaceuticals Proposes $75 Million IPO | - |
| 12.06.2020 | Biotechnology Company Checkmate Pharmaceuticals Raises $85 Million | Checkmate Pharmaceuticals, a clinical-stage biotechnology company that is focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced it has raised $85 million in Series C funding
Checkmate Pharmaceutical... |
| 10.06.2020 | Checkmate Pharmaceuticals Secures $85 Million in Series C Financing | - |
| 10.06.2020 | Checkmate Pharmaceuticals Secures $85 Million in Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 mi... |
| 10.06.2020 | Checkmate Pharmaceuticals Inks $85M in Series C |
CAMBRIDGE, MA, Checkmate Pharmaceuticals has completed an $85 million Series C financing.
>> Click here for more funding data on Checkmate Pharmaceuticals
>> To export Checkmate Pharmaceuticals funding data to PDF and Excel,... |
| 10.06.2020 | Checkmate Pharmaceuticals Raises $85M in Series C Financing | Checkmate Pharmaceuticals, a Cambridge, MA-based clinical stage biotechnology company with a novel approach to cancer immunotherapy, completed an $85m Series C financing.
The round was led by Longitude Capital and Novo Holdings with partici... |
| 10.06.2020 | Checkmate Pharmaceuticals Secures $85 Million in Series C Financing | - |
| 12.12.2018 | Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing | - |
| 12.12.2018 | Art Krieg moves from CEO post to CSO at Checkmate; Indivior breathes sigh of relief after court ruling | Art Krieg
→ Art Krieg is turning in his spot in the CEO’s suite in exchange for the CSO’s job at Checkmate Pharmaceuticals. Barry Labinger, former CEO at Biothera, will take the top job as Krieg — who founded the company — spen... |
| 12.12.2018 | Checkmate Pharmaceuticals Closes $22M Financing | Checkmate Pharmaceuticals Inc., a Cambridge, Mass.-based clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, closed $22m in financing.
The round was led by a new investor, Decheng Ca... |
| 05.09.2018 | What's up at Immunocore?; Pfizer nabs a key 'breakthrough'; Adaptimmune raises $100M | → What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer Kevin Pojasek is out, marking the latest in a long line of C-suite departure for the company. CEO Eliot Forster was first to depart,... |
| 13.11.2017 | Arcus Biosciences closes $107M Series C round as industry hunts for blockbuster immunotherapy combinations | Additional therapies are needed to double-down on the tumor and to close any potential escape routes.
On Monday, Arcus Biosciences closed a $107 million Series C round for its mission to provide that back-up support. The round was led by GV... |
| 16.06.2017 | Checkmate Pharmaceuticals Inks $27M Series B |
CAMBRIDGE, MA, Clinical-stage biopharmaceutical company has completed a $27 million Series B preferred financing led by new investor F-Prime Capital Partners.
>> Click here for more funding data on Checkmate Pharmaceuticals
>&g... |
| 15.06.2017 | Checkmate Pharmaceuticals Secures $27M Series B Funding | Checkmate Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, completed a $27m Series B financing.
The round was led by new investor F-Prime Cap... |
| 15.06.2017 | Checkmate Pharmaceuticals Raises $27 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals (Checkmate), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, announced that it has completed a $27 million Series B pre... |
| 12.08.2015 | Daily funding roundup - August 12, 2015 | PokitDoc closed $34M; Infogain secured $63M; Soothe raised $10.6M
If there's a service that I often book with little time in advance, it's getting a massage. It's hard to predict when you're neck or back will ache, and when you have a free ... |
| 12.08.2015 | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | Checkmate Pharmaceuticals operates on the idea that checkpoint inhibitor therapies would be much more effective if they were combined with an agent that could stimulate a person’s immune response. So, on top of the new financing, it’s also ... |
| 12.08.2015 | Checkmate Pharmaceuticals Nets $20M Series A |
CAMBRIDGE, MA, Biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, announced today their $20 million Series A financing.
>> Click here for more funding data on Checkmate Pharmaceuticals
>&... |
| 12.08.2015 | Checkmate Pharmaceuticals Raises $20M Series A Financing | Checkmate Pharmaceuticals, a Cambridge, MA-based biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, raised $20m Series A financing.
Backers included Sofinnova Ventures and venBio.
The company intends ... |
| - | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | The name of the company’s pretty pithy: Checkmate Pharmaceuticals, so-called because its drug in development serves as a “mate” to checkpoint inhibitors, enhancing their efficacy.
The Cambridge company just launched with a $20 million Serie... |
| - | Arcus Biosciences closes $107M Series C round as industry hunts for blockbuster immunotherapy combinations | Imagine cancer as a fugitive, hiding in a rundown warehouse. The police (aka the immune system) patrol the surrounding streets, oblivious to the deadly agent holed up inside.
Checkpoint inhibitors, on the market since 2010, help the good gu... |
| - | American Cancer Society’s BrightEdge to Invest in Checkmate Pharmaceuticals | BrightEdge, LLC, the American Cancer Society’s philanthropic impact fund, today announced its participation in the Series C funding round of Checkmate Pharmaceuticals (www.checkmatepharma.com), a clinical stage biopharmaceutical company foc... |
